No Data
RBC Capital Remains a Buy on Bachem Holding AG (0QND)
Bachem Holding AG Reports 1H Results
Guotai Haitong: Expansion of the peptide market is driving CDMO capacity expansion, with scale continuously growing alongside sales.
Peptide CDMO companies both domestically and internationally are increasing investments in capacity expansion, with particular emphasis on building integrated service capabilities spanning from preclinical development to commercial manufacturing.
ImmuPharma Taps Thermo Fisher as CDMO for Kapiglucagon Diabetes Program
Bachem to Invest Over CHF 500 Million in New Sisslerfeld Peptide Plant
Jefferies Reaffirms Their Sell Rating on Bachem Holding AG (0QND)